文献速递乳腺癌支持与姑息治疗

克隆性造血与曲妥珠单抗相关心脏毒性风险的关联研究

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.
PubMed 文献 · JAMA Oncol · 2026-01-01

该研究整合英国生物银行队列、首尔大学医院队列及小鼠实验,探讨不确定性潜能克隆性造血(CHIP)与乳腺癌患者曲妥珠单抗相关心脏毒性的关联。结果显示CHIP阳性与心脏毒性风险升高独立相关,Tet2缺陷小鼠在曲妥珠单抗暴露后左室射血分数显著下降。

要点

  • CHIP阳性乳腺癌患者接受曲妥珠单抗后心脏毒性风险约增近一倍(校正sHR 1.91)。
  • 不同心脏毒性定义下,CHIP阳性组2年累积发生率均高于阴性组。
  • Tet2缺陷小鼠曲妥珠单抗暴露后LVEF显著下降,支持机制关联。

核心结论

  • CHIP的存在与乳腺癌患者接受曲妥珠单抗后心脏毒性易感性增加相关。

研究设计与样本

  • 研究整合英国生物银行全国人群队列(2006-2010年入组)、首尔大学医院单中心队列(2004年1月至2024年3月入组)及受控动物实验。
  • 采用Fine-Gray竞争风险模型校正死亡和心肌梗死,多变量模型校正年龄和心血管危险因素,首尔大学医院队列额外校正蒽环类药物使用。

主要发现

  • 采用ESC定义,CHIP阳性(变异等位基因频率≥1.0%)与心脏毒性在多变量竞争风险分析中相关(校正sHR 1.91;95%CI 1.32-2.76)。

关键数值与推荐

  • 曲妥珠单抗相关心脏毒性依据ESC、加拿大曲妥珠单抗工作组和CREC既定临床标准定义。
  • CHIP阳性定义为变异等位基因频率≥1.0%。

临床怎么用

  • 对接受曲妥珠单抗的乳腺癌患者,可考虑评估CHIP状态以辅助识别心脏毒性高危人群。
  • CHIP阳性患者可能需要更密切的心功能监测和心血管危险因素管理。

局限性

  • 研究为观察性队列分析,不能确立因果关系。
  • 动物实验采用Tet2缺陷模型,结果外推至人类其他CHIP克隆需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP) is linked to an increased incidence of cardiovascular and malignant diseases. OBJECTIVE: To determine whether CHIP is associated with cardiotoxic effects in patients with breast cancer receiving trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: Analyses of human cohorts with complementary animal experimentation were performed using a nationwide population-based cohort (UK Biobank), 1 tertiary referral center (Seoul National University Hospital [SNUH]), and a controlled laboratory setting. UK Biobank participants were enrolled between 2006 and 2010, and SNUH patients were enrolled from January 2004 to March 2024. Data were analyzed from March 2021 to February 2026. MAIN OUTCOME MEASURES: Incident heart failure (HF) in the UK Biobank cohort and trastuzumab-related cardiotoxic effects in the SNUH cohort were the main outcome measures. Trastuzumab-related cardiotoxic effects were defined using established clinical criteria (European Society of Cardiology [ESC], Canadian Trastuzumab Working Group, and Cardiac Review and Evaluation Committee [CREC]). Fine-Gray competing risk models were used to account for death and myocardial infarction; multivariable models were adjusted for age and cardiovascular risk factors in both cohorts, with additional adjustment for anthracycline use in the SNUH cohort. Changes in left ventricular ejection fraction (LVEF) were assessed in Tet2-deficient bone marrow chimeric mice following trastuzumab exposure. RESULTS: Overall, 15 729 patients with breast cancer from the UK Biobank cohort (mean [SD] age, 58.8 [7.3] years; 107 [0.68%] male) and 454 female patients with breast cancer who received trastuzumab from the SNUH cohort (mean [SD] age, 52.0 [9.6] years) were included. The corresponding 2-year cumulative incidence values for trastuzumab-related cardiotoxic effects were 15.7% vs 5.0% by ESC criteria (Gray test P = .001), 19.9% vs 10.8% by Canadian criteria (P = .01), and 20.9% vs 11.3% by CREC criteria (P = .02). Using the ESC definition, CHIP positivity (variant allele frequency ≥1.0%) was associated with cardiotoxic effects in multivariable competing risk analysis (adjusted subdistribution hazard ratio, 1.91; 95% CI, 1.32-2.76). Tet2-deficient mice demonstrated a significant LVEF reduction following trastuzumab treatment (effect size, -4.2%; 95% CI, -7.91 to -0.49; P = .03); other experimental groups showed no significant change. CONCLUSIONS AND RELEVANCE: In this cohort study, the presence of CHIP was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Park CS, Ryu G, Ahn HJ, et al. Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects. JAMA Oncol. 2026. PMID: 41926089. doi:10.1001/jamaoncol.2026.0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。